Breakthrough results: cybin's cyb003 demonstrates remarkable interim data in treating major depressive disorder, achieving primary efficacy milestone and delivering prompt relief from depression symptoms with a single dose - comprehensive topline data anticipated by q4 2023

- interim readout shows rapid, robust, and clinically significant reduction of depression symptoms three weeks after a single 12mg dose, with an unprecedented mean -14 point montgomery-asberg depression rating scale ("madrs") score reduction from baseline between cyb003 (12mg) vs. placebo (p= 0.0005) - - for reference, pooled data from 232 industry studies of current standard of care antidepressants, selective serotonin reuptake inhibitors (ssris), submitted to u.s. food and drug administration ("fda") (stone et al, 2022) show an average improvement of 1.82 points vs.
CYBN Ratings Summary
CYBN Quant Ranking